APA (7th ed.) Citation

Raimondi, A., Tinè, G., De Stefano, A., Ballhausen, A., Bouche, O., Morano, F., . . . Pietrantonio, F. (2025). 39P AntiEGFR-based maintenance versus stop&go strategy in patients with left-sided, non MSI, RAS/BRAF wild type (wt) metastatic colorectal cancer (mCRC): Individual patient data (IPD) pooled analysis of randomized clinical trials (RCTs). Annals of Oncology, 36, S24. https://doi.org/10.1016/j.annonc.2025.05.051

Chicago Style (17th ed.) Citation

Raimondi, A., et al. "39P AntiEGFR-based Maintenance Versus Stop&go Strategy in Patients with Left-sided, Non MSI, RAS/BRAF Wild Type (wt) Metastatic Colorectal Cancer (mCRC): Individual Patient Data (IPD) Pooled Analysis of Randomized Clinical Trials (RCTs)." Annals of Oncology 36 (2025): S24. https://doi.org/10.1016/j.annonc.2025.05.051.

MLA (9th ed.) Citation

Raimondi, A., et al. "39P AntiEGFR-based Maintenance Versus Stop&go Strategy in Patients with Left-sided, Non MSI, RAS/BRAF Wild Type (wt) Metastatic Colorectal Cancer (mCRC): Individual Patient Data (IPD) Pooled Analysis of Randomized Clinical Trials (RCTs)." Annals of Oncology, vol. 36, 2025, p. S24, https://doi.org/10.1016/j.annonc.2025.05.051.